BR9714523A - Tratamento de nefrite de lúpus com compostos anti-cd40l - Google Patents

Tratamento de nefrite de lúpus com compostos anti-cd40l

Info

Publication number
BR9714523A
BR9714523A BR9714523-8A BR9714523A BR9714523A BR 9714523 A BR9714523 A BR 9714523A BR 9714523 A BR9714523 A BR 9714523A BR 9714523 A BR9714523 A BR 9714523A
Authority
BR
Brazil
Prior art keywords
treatment
cd40l compounds
lupus nephritis
cd40l
compounds
Prior art date
Application number
BR9714523-8A
Other languages
English (en)
Inventor
Susam L Kalled
David W Thomas
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR9714523A publication Critical patent/BR9714523A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"TRATAMENTO DE NEFRITE DE LúPUS COM COMPOSTOS ANTI-CD40L"<D>. São fornecidos métodos para o tratamento da nefrite associada com uma doença de complexo imune com compostos anti-CD40L. Em uma seção, os compostos anti-CD40L são administrados a um paciente com doença de complexo imune, que recebeu um aloenxerto de rim, para inibirem o desenvolvimento da glomerulonefrite de complexo imune dentro do rim enxertado.
BR9714523-8A 1997-01-10 1997-12-31 Tratamento de nefrite de lúpus com compostos anti-cd40l BR9714523A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3467397P 1997-01-10 1997-01-10
PCT/US1997/023482 WO1998030240A1 (en) 1997-01-10 1997-12-31 Treatment of lupus nephritis with anti-cd40l compounds

Publications (1)

Publication Number Publication Date
BR9714523A true BR9714523A (pt) 2000-05-02

Family

ID=21877889

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714523-8A BR9714523A (pt) 1997-01-10 1997-12-31 Tratamento de nefrite de lúpus com compostos anti-cd40l

Country Status (19)

Country Link
US (2) US20030031668A1 (pt)
EP (2) EP0948355A1 (pt)
JP (1) JP2001508441A (pt)
KR (2) KR100618081B1 (pt)
CN (2) CN1247472A (pt)
AU (1) AU5709798A (pt)
BR (1) BR9714523A (pt)
CA (1) CA2277222A1 (pt)
CZ (1) CZ297680B6 (pt)
EA (2) EA006314B1 (pt)
EE (1) EE9900273A (pt)
HU (1) HUP0000833A3 (pt)
IL (1) IL130784A0 (pt)
IS (1) IS5100A (pt)
NO (1) NO993274L (pt)
NZ (1) NZ337072A (pt)
PL (1) PL190663B1 (pt)
TR (7) TR200001247T2 (pt)
WO (1) WO1998030240A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
HUP0101689A3 (en) * 1998-04-03 2004-08-30 Trustees Of Darmouth College H Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
IL126681A0 (en) * 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
CN100369932C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人cd154单克隆抗体及其应用
JP2012511014A (ja) * 2008-12-05 2012-05-17 エイエルエス・セラピー・デベロップメント・インスティテュート 神経変成疾患を治療する方法
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
US20130310266A1 (en) * 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
HK1252815A1 (zh) * 2015-08-31 2019-06-06 默克专利有限公司 调节lgals3bp以治疗系统性红斑狼疮的方法
SG10202111207TA (en) 2017-05-24 2021-11-29 Als Therapy Development Inst Therapeutic anti-cd40 ligand antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20230152032A (ko) 2021-02-03 2023-11-02 모차르트 쎄라퓨틱스 인코포레이티드 결합제 및 이를 사용하는 방법
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2026092377A1 (zh) * 2024-10-28 2026-05-07 信达生物制药(苏州)有限公司 用cd40l抗体治疗自身免疫病

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
CA2243531A1 (en) * 1996-01-16 1997-07-24 The Trustees Of Columbia University In The City Of New York Therapeutic applications of t-bam (cd40-l) technology to treat inflammatory kidney diseases______________________________________
AU2593997A (en) * 1996-03-21 1997-10-10 Trustees Of Columbia University In The City Of New York, The Craf1 (traf-3) isoforms and uses thereof

Also Published As

Publication number Publication date
JP2001508441A (ja) 2001-06-26
TR200001247T2 (tr) 2002-06-21
IL130784A0 (en) 2001-01-28
CZ297680B6 (cs) 2007-03-07
TR200001248T2 (tr) 2000-07-21
US20030031668A1 (en) 2003-02-13
EE9900273A (et) 2000-02-15
PL190663B1 (pl) 2005-12-30
TR199902191T2 (xx) 1999-12-21
EA199900636A1 (ru) 2000-02-28
CA2277222A1 (en) 1998-07-16
EA006314B1 (ru) 2005-10-27
EP1357131A2 (en) 2003-10-29
PL334495A1 (en) 2000-02-28
NO993274D0 (no) 1999-07-01
TR200001246T2 (tr) 2000-07-21
HUP0000833A2 (en) 2000-07-28
WO1998030240A1 (en) 1998-07-16
EP1357131A3 (en) 2004-02-11
CZ244499A3 (cs) 1999-10-13
NZ337072A (en) 2000-12-22
EP0948355A1 (en) 1999-10-13
AU5709798A (en) 1998-08-03
CN1247472A (zh) 2000-03-15
KR100618081B1 (ko) 2006-08-30
KR20050089165A (ko) 2005-09-07
TR200001250T2 (tr) 2001-03-21
TR200001249T2 (tr) 2000-11-21
TR200001251T2 (tr) 2000-09-21
IS5100A (is) 1999-06-30
EA200501076A1 (ru) 2006-06-30
US20070190053A1 (en) 2007-08-16
CN1572325A (zh) 2005-02-02
HUP0000833A3 (en) 2001-09-28
KR20000070034A (ko) 2000-11-25
NO993274L (no) 1999-09-10

Similar Documents

Publication Publication Date Title
EP1357131A3 (en) Treatment of lupus nephritis with anti-CD4OL compounds
BR9913645A (pt) Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
NO20014415L (no) Medisinske preparater til behandling av &lt;alfa&gt;-galaktosidase- A-defisiens
ATE318845T1 (de) Therapeutische multispezifische verbindungen, die antikörper gegen den fcalpha-rezeptor enthalten
ITTO950104A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
BR0111562A (pt) Análogos de peptìdeo 1 semelhantes ao glucagon
ITTO950099A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
TR199800585T2 (xx) COX-2 �nhibit�rleri Olarak (Metils�lfonil)Fenil-2-(5H)-Furanonlar.
AU5624699A (en) Use of 5ht-6 antagonists
DK0998287T3 (da) Anvendelse af levobupivacain
UA86582C2 (ru) Способ лечения хореи гентингтона ейкозапентеновой кислотой
DE69905368D1 (en) Oxydiertes thymosin beta 4
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
AP9400647A0 (en) Medicaments for use in treatment of HIV or cancer patients.
KR960028907A (ko) 암환자를 치료하기 위한 세트랄린의 용도
AU2739497A (en) Use of vitamin d analogs for the treatment of arthritic disease
AU2001232053A1 (en) System for the extracorporeal treatment of blood
EP0990441A4 (en) MEDICINES FOR TREATING DIABETIC NEPHROSIS
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
ZA991783B (en) Therapeutic treatment for autoimmune diseases.
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung
AU5890499A (en) Use of composition in the treatment of schizophrenia
WO2002088345A3 (en) Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA, INC. (US)

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA INC. (US)

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.